ECSP045087A - NEW FORMULATION OF DRY AND WATER EPINASTINE SYRUP - Google Patents

NEW FORMULATION OF DRY AND WATER EPINASTINE SYRUP

Info

Publication number
ECSP045087A
ECSP045087A EC2004005087A ECSP045087A ECSP045087A EC SP045087 A ECSP045087 A EC SP045087A EC 2004005087 A EC2004005087 A EC 2004005087A EC SP045087 A ECSP045087 A EC SP045087A EC SP045087 A ECSP045087 A EC SP045087A
Authority
EC
Ecuador
Prior art keywords
epinastine
syrup
dry
water
new formulation
Prior art date
Application number
EC2004005087A
Other languages
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045087A publication Critical patent/ECSP045087A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente invención se refiere a una nueva formulación de epinastina en forma de polvo (jarabe seco) para ser mezclada con agua antes de usarse. La epinastina puede usarse como base libre o bien como sal de la misma aceptable farmacéuticamente. La epinastina, entre otras cosas, se aplica al tratamiento de alergias, dolor, en particular el dolor crónico y el dolor producido por una inflamación, la migraña, el asma, la rinitis, la conjuntivitis y/o la bronquitis. En particular, la formulación es para el tratamiento de alergias, dermatitis, rinitis, conjuntivitis, bronquitis y asma.The present invention relates to a new formulation of epinastine in powder form (dry syrup) to be mixed with water before use. Epinastine can be used as a free base or as a pharmaceutically acceptable salt thereof. Epinastine, among other things, applies to the treatment of allergies, pain, particularly chronic pain and pain caused by inflammation, migraine, asthma, rhinitis, conjunctivitis and / or bronchitis. In particular, the formulation is for the treatment of allergies, dermatitis, rhinitis, conjunctivitis, bronchitis and asthma.

EC2004005087A 2001-10-26 2004-04-26 NEW FORMULATION OF DRY AND WATER EPINASTINE SYRUP ECSP045087A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152973A DE10152973A1 (en) 2001-10-26 2001-10-26 New dry and watery Epinastin syrup formulation

Publications (1)

Publication Number Publication Date
ECSP045087A true ECSP045087A (en) 2004-06-28

Family

ID=7703856

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005087A ECSP045087A (en) 2001-10-26 2004-04-26 NEW FORMULATION OF DRY AND WATER EPINASTINE SYRUP

Country Status (9)

Country Link
EP (1) EP1448204A1 (en)
JP (2) JP4564749B2 (en)
KR (1) KR20050034619A (en)
BR (1) BR0213488A (en)
CO (1) CO5580751A2 (en)
DE (1) DE10152973A1 (en)
EC (1) ECSP045087A (en)
MX (1) MXPA04003772A (en)
WO (1) WO2003037350A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452177A1 (en) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
JP2007530481A (en) * 2004-03-24 2007-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more herbal medicines
JP5132090B2 (en) * 2006-06-16 2013-01-30 東和薬品株式会社 Epinastine hydrochloride dry syrup
CN105708808B (en) * 2014-12-01 2018-11-27 重庆安格龙翔医药科技有限公司 A kind of epinastine hydrochloride granule and preparation method thereof
CN105708840A (en) * 2014-12-01 2016-06-29 重庆安格龙翔医药科技有限公司 Epinastine hydrochloride composition
CN105708807B (en) * 2014-12-01 2018-11-27 重庆安格龙翔医药科技有限公司 A kind of preparation method of epinastine hydrochloride granula subtilis
JP2020172486A (en) * 2019-04-10 2020-10-22 参天製薬株式会社 Aqueous pharmaceutical composition containing epinastine or salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (en) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim DIBENZIMIDAZOAZEPINE, THEIR PRODUCTION AND USE
EP0658340A1 (en) * 1993-12-17 1995-06-21 Unilever N.V. Oral compositions
JPH0827034A (en) * 1994-07-14 1996-01-30 Nikken Chem Co Ltd Liquid agent for internal use containing erythritol
JPH0952849A (en) * 1995-06-06 1997-02-25 Taisho Pharmaceut Co Ltd Composition for cold remedy
DE19542281C2 (en) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Use of Epinastin for the treatment of migraines
JPH1045576A (en) * 1996-08-05 1998-02-17 Taisho Pharmaceut Co Ltd Orally administering agent for rhinitis
EP1020193A4 (en) * 1997-09-30 2006-05-24 Daiichi Seiyaku Co Oral preparation
JPH11302189A (en) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd Composition for cold
PT1138333E (en) * 1999-10-12 2004-07-30 Daiichi Suntory Pharma Co Ltd ORAL PHARMACEUTICAL COMPOSITION

Also Published As

Publication number Publication date
KR20050034619A (en) 2005-04-14
CO5580751A2 (en) 2005-11-30
WO2003037350A1 (en) 2003-05-08
MXPA04003772A (en) 2004-07-30
EP1448204A1 (en) 2004-08-25
DE10152973A1 (en) 2003-05-08
JP4564749B2 (en) 2010-10-20
JP2010132702A (en) 2010-06-17
JP2005508364A (en) 2005-03-31
BR0213488A (en) 2004-11-03

Similar Documents

Publication Publication Date Title
CL2007002450A1 (en) Polymorphic form i of the enantiomer levogiro or dextrogiro of modafinil; its preparation procedure; and pharmaceutical composition comprising them (divisional application 2693-03).
AR054833A1 (en) DOSAGE FORMS OF DELAYED ORAL DELAY Highly bi-available O-DEMETILVENLAFAXINA SUCCINATE
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
CR10167A (en) "USE OF BENZO-FUSIONED SULFAMIDE DERIVATIVES FOR PAIN TREATMENT"
EP1575536A4 (en) Topical use of post-application expanding cosmetic composition
ECSP045087A (en) NEW FORMULATION OF DRY AND WATER EPINASTINE SYRUP
NO20033742D0 (en) Omega-aminoalkylamides of R-2-arylpropionic acids as inhibitors of polymophonuclear and mononuclear cells chemotaxis
CR9723A (en) NEW CRYSTAL FORM OF A PIRIDAZINO DERIVATIVE [4,5-B] INDOL
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
AR062857A1 (en) BEVERAGE CREAM
IS7820A (en) Compositions containing melatonin, temple and biotin
ATE331711T1 (en) ANTI-INFLAMMATORY 3-ARYLTHIO-3-THIAZOLYLALKYLAMINE
UY28524A1 (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
WO2002017898A3 (en) Compositions and methods for inducing vasorelaxation
AU2002243451A1 (en) Use of catecholamine reuptake inhibitors to enhance memory
MD4093B1 (en) Use of topical pharmaceutical composition containing ambroxol
IS6426A (en) Piperazinomethylbenzamide as delta-opioid receptor agonist
NO20024724D0 (en) Prophylactic and therapeutic use of oltipraz as antifibrotic and anti-cirrhotic agent in the liver and monopharmaceutical composition containing oltipraz
IL161036A0 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
BR0312604A (en) imido-alkanecarboxylic acids, compositions, and, process for the preparation and use of imido-alkanecarboxylic acids
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AR041999A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AMBROXOL AND ISOPROPAMIDE IODURE
NO20055515D0 (en) 7-azaindoles and their use as therapeutic agents
AR031720A1 (en) BENZIMIDAZOLES N-ALCOXIALQUIL SUBSTITUTED, PROCESS FOR THE PREPARATION, COMPOSITIONS, AND USE OF THESE COMPOUNDS TO PREPARE ANTIPARASITARY COMPOSITIONS